Drug Trial Radar · NCT07682961
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
850
Planned (sponsor's estimate)
Start
Jul 14, 2026
Primary completion
Mar 2029
Study completion Mar 2033
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jul 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to compare how effective a long-acting injectable treatment of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) versus (CAB) and rilpivirine (RPV) injections given every 8 weeks in adults with HIV-1 whose virus is well controlled on daily oral treatment, after 1 year (52 weeks) of the treatment. The primary objective of this study are to evaluate the efficacy of switching to the regimen of LEN, TAB, and ZAB versus switching to CAB and RPV in virologically suppressed people with HIV-1 (PWH) as determined by the proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 52.
Conditions
- HIV Infections
Interventions
LenacapavirDrug
Administered subcutaneously
Lenacapavir TabletDrug
Administered orally
TeropavimabDrug
Administered intravenously (IV)
ZinlirvimabDrug
Administered IV
CabotegravirDrug
Administered intramuscular (IM)
RilpivirineDrug
Administered IM
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants With HIV-1 ribonucleic acid (RNA) ≥ 50 Copies/mL at Week 52 as Defined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm.Time frame: Week 52
Locations
61 sites in 8 countries. Site status is shown where the registry gives one.
Franco Felizarta Md
Bakersfield, California · Recruiting
Pacific Oaks Medical Group
Beverly Hills, California · Recruiting
Metro Infectious Disease Consultants, P. L. L. C
Hidden Valley Lake, California · Recruiting
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California · Recruiting
Optimus Medical Group
San Francisco, California · Recruiting
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California · Recruiting
Yale University; School of Medicine; AIDS Program
New Haven, Connecticut · Recruiting
Washington Health Institute
Washington D.C., District of Columbia · Recruiting
Midland Florida Clinical Research Center, LLC
DeLand, Florida · Recruiting
CAN Community Health Fort Lauderdale
Fort Lauderdale, Florida · Recruiting
Midway Immunology and Research Center
Ft. Pierce, Florida · Recruiting
CAN Community Health Miami Gardens
Miami Gardens, Florida · Recruiting
Midland Medical
Oakland Park, Florida · Recruiting
BLISS Health Inc.
Orlando, Florida · Recruiting
Orlando Immunology Center, PA
Orlando, Florida · Recruiting
CAN Community Health
Sarasota, Florida · Recruiting
MOORE Clinical Research, Inc d/b/a TrueBlue Clinical Research
Tampa, Florida · Recruiting
Triple O Research Institute, P.A.
West Palm Beach, Florida · Recruiting
Atlantic Clinical Research Institute
West Palm Beach, Florida · Recruiting
Grady Health System, Ponce de Leon Center
Atlanta, Georgia · Recruiting
Atlanta ID Group, PC
Atlanta, Georgia · Recruiting
Mercer University, Department of Internal Medicine
Macon, Georgia · Recruiting
Chatham County Health Department
Savannah, Georgia · Recruiting
Metro Infectious Disease Consultants
Burr Ridge, Illinois · Recruiting
Howard Brown Health Center
Chicago, Illinois · Recruiting
Be Well Medical Center
Berkley, Michigan · Recruiting
KC CARE Health Center
Kansas City, Missouri · Recruiting
AXCES Research Group, LLC
Sante Fe, New Mexico · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
Rosedale Health and Wellness
Huntersville, North Carolina · Recruiting
Wilmington Health
Wilmington, North Carolina · Recruiting
University of Cincinnati College of Medicine
Cincinnati, Ohio · Recruiting
North Texas Infectious Diseases Consultants, P.A.
Dallas, Texas · Recruiting
Texas Centers for Infectious Disease Associates
Forth Worth, Texas · Recruiting
AXCES Research Group, LLC
Salt Lake City, Utah · Recruiting
Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID)
Annandale, Virginia · Recruiting
TribalMed PLLC
Seattle, Washington · Recruiting
Taylor Square Private Clinic
Surry Hills, New South Wales, Australia · Recruiting
Momentum Clinical Research Darlinghurst
Sydney, New South Wales, Australia · Recruiting
East Sydney Doctors
Sydney, New South Wales, Australia · Recruiting
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.